Skip to main content

Table 4 Sensitivity analysis

From: Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

No.

Study that leave

OR rate

CR rate

RR

Relative rate (95% CI)

I2 (%)

p-value

Relative rate (95% CI)

I2 (%)

p-value

Relative rate (95% CI)

I2 (%)

p-value

A4

Berentsen (2006)

1.09 (1.00, 1.19)

34.44

0.14

1.15 (0.98, 1.35)

48.37

0.05

   

A12

Michel (2009)

1.20 (1.02, 1.40)

75.15

0.00

1.19 (0.99, 1.43)

56.56

0.02

0.96 (0.55, 1.71)

48.42

0.07

A18

Birgens (2013)

1.20 (1.03, 1.39)

74.94

0.00

1.18 (0.99, 1.41)

55.56

0.02

   

A20

Barcellini (2014)

1.22 (1.02, 1.45)

75.07

0.00

1.21 (0.98, 1.48)

56.95

0.02

0.99 (0.54, 1.83)

46.25

0.08

A21

Roumier (2014)

1.18 (1.01, 1.37)

74.80

0.00

1.12 (0.95, 1.33)

47.14

0.06

0.90 (0.47, 1.73)

48.42

0.07

A23

Fu (2016)

1.22 (1.02, 1.46)

75.17

0.00

1.16 (0.97, 1.40)

56.23

0.02

0.88 (0.49, 1.56)

46.94

0.08

A27

Michel (2017)

1.15 (1.00, 1.32)

71.68

0.00

1.13 (0.96, 1.34)

48.94

0.05

0.96 (0.56, 1.65)

47.72

0.07

M7

Froissart (2012)

1.16 (0.99, 1.37)

71.24

0.00

1.15 (0.93, 1.41)

40.60

0.10

0.83 (0.49, 1.56)

39.83

0.13

M9

Hie (2014)

1.19 (1.02, 1.38)

75.20

0.00

1.18 (0.98, 1.44)

57.31

0.02

1.09 (0.74, 1.60)

0.00

0.47

M10

Khandelwal (2014)

1.23 (1.04, 1.46)

70.04

0.00

1.24 (1.03, 1.49)

25.52

0.22

0.83 (0.50, 1.35)

32.18

0.18